Founded with a mission to revolutionize chronic disease management, Aptatek Biosciences develops portable, home-based monitoring devices aimed at improving patient compliance and quality of life. The company’s initial focus is on Phenylketonuria (PKU), a condition requiring lifelong monitoring of phenylalanine levels. Utilizing proprietary aptamer technology, Aptatek offers a smartphone-based test platform that allows patients to monitor their condition from home, eliminating the need for hospital visits or mailing blood samples.
Aptatek has garnered significant recognition, including the FDA's Breakthrough Device designation for its PKU monitoring test. The company's leadership includes experts in biotechnology and medical device development, supported by a network of investors committed to advancing healthcare innovation. Aptatek's impact lies in its potential to transform chronic disease management, making it more accessible and convenient for patients worldwide.
